Chemoneuroendocrine therapy of metastatic breast cancer with persistent thrombocytopenia with weekly low-dose epirubicin plus melatonin: A phase II study

Journal of Pineal Research

Volumn 26, Issue 3, 1999, Pages 169-173

  Lissoni, P ^a,b   Tancini, G ^a   Paolorossi, F ^a   Mandala M ^a   Ardizzoia, A ^a   Malugani, F ^a   Giani, L ^a   Barni, S ^a  

^a SAN GERARDO HOSPITAL   (Italy)

^b Divisione di Radioterapia A   (Italy)

Author keywords

Anthracyclines; Breast cancer; Melatonin; Thrombocytopenia

Indexed keywords

CYTOKINE; EPIRUBICIN; MELATONIN; NEUROHORMONE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFECT; FEMALE; HEMATOPOIETIC CELL; HUMAN; MEGAKARYOCYTE; ORAL DRUG ADMINISTRATION; PINEAL BODY; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; TUMOR REGRESSION;

EID: 0032934895     PISSN: 07423098     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-079X.1999.tb00579.x     Document Type: Article

References (15)

1. Cairo, M.S., J.M. Plunkett, A. Nguyen, P. Schendel, C. Van De Ven (1993) Effect of interleukin-11 with and without granulocyte colony-stimulating factor on in vivo neonatal rat hematopoiesis. Pediatr. Res. 34:56-61.
2. WAFI CIPI via C/EBPβ. Nature Med. 3:1233-1238.
3. De Vita, V.T. (1978) The evaluation of therapeutic research in cancer. N. Engl. J. Med. 289:907-910.
4. Kaushiansky, K. (1995) Thrombopoietin: the primary regulator of platelet production. Blood 86:419-431.
5. Lissoni, P., G. Tancini, S. Barni, F. Paolorossi, F. Rossini, P.F. Maffe, L. Di Bella (1996) The pineal hormone melatonin in hematology and its efficacy in the treatment of thrombocytopenia. Rec. Progr. Med. 87:581-585.
6. Montilla, P., I. Tunez, M.C. Munoz, A. Lopez, J.V. Soria (1997) Hyperlipidemic nephropathy induced by adriamycin: Effect of melatonin administration. Nephron 76:345-350.
7. Myers, C.E. (1987) Anthracyclines. In: Cancer Chemotherapy and Biological Response Modifiers, H.M. Pinedo, D.L. Longo, B.A. Chabner, eds. Elsevier, Amsterdam, pp. 36-49.
8. Platanias, L.C., N.J. Vogelzang (1990) Interleukin-1: Biology, pathophysiology, and clinical prospects. Am. J. Med. 89:621-629.
9. Postmus, P.E., J.A. Gietema, O. Damsma, B. Biesma, P.C. Limburg, E. Vellenga, E.G.E. De Vries (1992) Effects of recombinant human interleukin-3 in patients with relapsed small cell lung cancer treatment with chemotherapy: A dose-finding study. J. Clin. Oncol. 10:1131-1140.
10. Reiter, R.J., R.C. Carneiro, C.-S. Oh (1997a) Melatonin in relation to cellular antioxidative defense mechanisms. Horm. Metab. Res. 29:363-372.
11. Reiter, R.J., L. Tang, J.J. Garcia, A. Munoz-Hoyos (1997b) Pharmacological actions of melatonin in oxygen radical pathophysiology. Life Sci. 60:2255-2271.
12. Regelson, W., W. Pierpaoli (1987) Melatonin: a rediscovered antitumor hormone? Its relation to surface receptors, sex, steroid metabolism, immunologic response, and chrono-biological factors in tumor growth and therapy. Cancer Invest. 5:379-385.
13. Sharp, A.A. (1977) Diagnosis and management of cancer. Br. Med. Bull. 33:265-272.
14. Vacas, M.L. M.M. Del-Zar, M. Martinuzzp, D.P. Cardinali (1992) Binding sites for 3H-melatonin in human platelets. J. Pineal. Res. 13:60-65.
15. Van Snick, J. (1990) Interleukin-6: an overview. Ann. Rev. Immun. 8:253-278.